Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine Radiolabel

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/B:BREA.0000018417.02580.efPMID 14999147
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved iodine radiolabels for monoclonal antibody therapy.

  2003influential reference
• Targeted therapy of cancer with radiolabeled antibodies.

  2002cited by this paper
• Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine.

  2001cited by this paper
• Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.

  1999cited by this paper
• Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.

  1999cited by this paper
• Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids.

  1999cited by this paper
• Humanization of Immu31, an alpha-fetoprotein-specific antibody.

  1999cited by this paper
• Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.

  1999cited by this paper
• Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.

  1998cited by this paper
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  1998cited by this paper
• Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.

  1997cited by this paper
• Generation of a high‐producing clone of a humanized anti‐B‐cell lymphoma monoclonal antibody (hLL2)

  1997cited by this paper
• Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.

  1997cited by this paper
• Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.

  1995cited by this paper
• Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle.

  1995cited by this paper
• Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.

  1995influential reference
• In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer.

  1995cited by this paper
• Processing of antibody‐radioisotope conjugates after binding to the surface of tumor cells

  1994cited by this paper
• Absorbed fractions for electrons and beta particles in spheres of various sizes.

  1994cited by this paper
• High dose chemotherapy with autologous stem cell support for the treatment of metastatic breast cancer

  1994influential reference
• The biologic window for chimeric l6 radioimmunotherapy

  1994cited by this paper
• Multidisciplinary management of advanced primary and metastatic breast cancer

  1994cited by this paper
• Characterization of cluster 13: The epithelial/carcinoma antigen recognized by MAb RS7

  1994cited by this paper
• The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels.

  1994cited by this paper
• Specificity and properties of MAb RS7‐3G11 and the antigen defined by this pancarcinoma monoclonal antibody

  1993cited by this paper
• Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells.

  1991cited by this paper
• Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: specificity and tumor targeting.

  1990cited by this paper
• Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

  1984cited by this paper
• Tissue sulfhydryl groups.

  1959cited by this paper

• The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors

  2025cites this paper
• Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors

  2025cites this paper
• The therapeutic antibody sacituzumab induces trophoblast cell-surface antigen-2 conformational rearrangement.

  2025cites this paper
• TROP2-targeted molecular imaging: a promising tool for precision oncology.

  2025cites this paper
• Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook.

  2024cites this paper
• Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine

  2024cites this paper
• Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth

  2024cites this paper
• Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models

  2022cites this paper
• A literature review of the promising future of TROP2: a potential drug therapy target

  2022cites this paper
• Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors

  2021cites this paper
• 89Zr and 177Lu labeling of anti-DR5 monoclonal antibody for colorectal cancer targeting PET-imaging and radiotherapy

  2021cites this paper
• Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics

  2021cites this paper
• Recent Advances in Trop 2 Targeted Therapy for Solid Tumors

  2020cites this paper
• Antibody Drug and Radionuclide Conjugates for GI Cancers

  2017cites this paper
• The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer

  2016cites this paper
• Prospects and progress of antibody-drug conjugates in solid tumor therapies

  2016cites this paper
• Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma

  2016cites this paper
• Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)

  2015cites this paper
• Trop2: From development to disease

  2015cites this paper
• Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications

  2015cites this paper
• Expression of tumor-associated calcium signal transducer 2 in patients with salivary adenoid cystic carcinoma: Correlation with clinicopathological features and prognosis

  2014cites this paper
• Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway

  2013cites this paper
• TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas

  2013cites this paper
• Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer.

  2013cites this paper
• TROP2 Correlates with Microvessel Density and Poor Prognosis in Hilar Cholangiocarcinoma

  2013cites this paper
• The Role of Trop2 Cleavage Products in Prostate Tumorigenesis

  2013cites this paper
• Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling.

  2012cites this paper
• A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2–Expressing Epithelial Cancers

  2012cites this paper
• Radioimmunotherapy of Tumors: Pretargeting with Bispecific Antibodies

  2012cites this paper
• catenin signaling β stem cell self-renewal via Regulated proteolysis of Trop 2 drives epithelial hyperplasia and Material Supplemental

  2012cites this paper
• Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors

  2011cites this paper
• High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

  2011cites this paper
• Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody

  2011cites this paper
• Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

  2011cites this paper
• Uterine serous papillary carcinomas overexpress human trophoblast‐cell‐surface marker (trop‐2) and are highly sensitive to immunotherapy with hRS7, a humanized anti‐trop‐2 monoclonal antibody

  2011influential citation
• Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

  2011cites this paper
• Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma: Implications for Immunotherapy With hRS7, a Humanized Anti–Trop-2 Monoclonal Antibody

  2011cites this paper
• Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients.

  2010cites this paper
• Trop2: a possible therapeutic target for late stage epithelial carcinomas.

  2009cites this paper
• TROP2 expression as prognostic marker for gastric carcinoma

  2008cites this paper
• TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity

  2008cites this paper
• High expression of TROP2 correlates with poor prognosis in pancreatic cancer

  2008cites this paper
• Emerging Role of Platelet-Derived Growth Factor Receptor-β Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer

  2007cites this paper
• Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.

  2006cites this paper
• Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy.

  2005cites this paper
• Development of humanized antibodies as cancer therapeutics.

  2005cites this paper
• Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody

  2005cites this paper
• Anti-CD 74 Antibody-Doxorubicin Conjugate , IMMU-110 , in a HumanMultipleMyeloma Xenograft and inMonkeys

  2005cites this paper
• Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies

  2005cites this paper
• Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys

  2005cites this paper
• Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.

  2004cites this paper
• CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy

  2004cites this paper
• of tumor-associated calcium signal transducer 2 in patients with salivary adenoid cystic carcinoma: Correlation with clinicopathological features and prognosis

  year unknowncites this paper